JAMA Oncology
Comment & Response
April 11, 2024
Yongwoo David聽Seo,听惭顿; Seth M.听Pollack,听惭顿
online first
JAMA Oncol. 2024; 10.1001/jamaoncol.2024.0311
JAMA Oncology
Original Investigation
October 12, 2023
Yongwoo David聽Seo,听惭顿; Hailing聽Lu,听惭顿, PhD; Graeme聽Black,聽BS; Kimberly聽Smythe,聽BS; Yuexin聽Yu,聽PhD; Cynthia聽Hsu,聽BS; Juliana聽Ng,聽BS; Pedro聽Hermida de Viveiros,听惭顿; E. Houston聽Warren,听惭顿, PhD; Brett A.听Schroeder,听惭顿; Ryan B.听O鈥橫alley,听惭顿; Lee D.听Cranmer,听惭顿, PhD; Elizabeth T.听Loggers,听惭顿, PhD; Michael J.听Wagner,听惭顿; Lynn聽Bonham,聽PhD; Venu G.听Pillarisetty,听惭顿; Gabrielle聽Kane,听惭顿; Peter聽Berglund,聽PhD; Frank J.听Hsu,听惭顿; Xinlei聽Mi,聽PhD; Borislav A.听Alexiev,听惭顿; Robert H.听Pierce,听惭顿; Stanley R.听Riddell,听惭顿; Robin L.听Jones,听惭顿; Jan聽ter Meulen,听惭顿, PhD; Edward Y.听Kim,听惭顿; Seth M.听Pollack,听惭顿
open access
JAMA Oncol. 2023; 9(12):1660-1668. 10.1001/jamaoncol.2023.4015
This nonrandomized controlled trial of patients with advanced soft tissue sarcoma analyzed the immunomodulatory effects of intratumoral glycopyranosyl lipid A in stable-emulsion formulation with concurrent radiotherapy.
JAMA Oncology
Comment & Response
January 28, 2021
Michael J.听Wagner,听惭顿; Lee D.听Cranmer,听惭顿, PhD; Seth M.听Pollack,听惭顿
JAMA Oncol. 2021; 7(3):465-466. 10.1001/jamaoncol.2020.7873
JAMA Oncology
Brief Report
September 10, 2020
Seth M.听Pollack,听惭顿; Mary W.听Redman,聽PhD; Kelsey K.听Baker,聽MS; Michael J.听Wagner,听惭顿; Brett A.听Schroeder,听惭顿; Elizabeth T.听Loggers,听惭顿, PhD; Kathryn聽Trieselmann,聽PharmD; Vanessa C.听Copeland,聽PharmD; Shihong聽Zhang,聽PhD; Graeme聽Black,聽BS; Sabrina聽McDonnell,聽MS; Jeffrey聽Gregory,聽BS; Rylee聽Johnson,聽BS; Roxanne聽Moore,聽BS; Robin L.听Jones,听惭顿; Lee D.听Cranmer,听惭顿, PhD
open access
JAMA Oncol. 2020; 6(11):1778-1782. 10.1001/jamaoncol.2020.3689
This nonrandomized clinical trial evaluates the use of doxorubicin and pembrolizumab in patients with metastatic/unresectable anthracycline-naive sarcoma.